Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Dalla Volta A, Valcamonico F, Zivi A, Procopio G, Sepe P, Del Conte G, Di Meo N, Foti S, Zamboni S, Messina C, Lucchini E, Rizzi A, Ravanelli M, Calza S, Zacchi F, Ciccone G, Suardi N, Maroldi R, Farina D, Berruti A.
Dalla Volta A, et al. Among authors: sepe p.
Eur Urol. 2024 May 20:S0302-2838(24)02347-9. doi: 10.1016/j.eururo.2024.05.004. Online ahead of print.
Eur Urol. 2024.
PMID: 38772788
No abstract available.